Full-Time

Manager of Process Engineering

Posted on 11/30/2025

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Marlborough, MA, USA

In Person

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor’s degree in Engineering (Mechanical, Electrical, Chemical, or similar) or a related field
  • 7+ years of engineering experience within a biotech, pharmaceutical, or CDMO environment, with at least 3+ years in a leadership role
  • Strong understanding of GMP, FDA regulations, and other applicable regulatory guidelines
  • Proven experience in process engineering, equipment design, project management, and change control in a regulated environment for novel therapeutics, including cell and gene therapy
  • Knowledge of validation protocol (IQ, OQ, PQ) and equipment qualification
  • Familiarity with bioprocessing equipment (e.g., bioreactors, chromatography systems) and cleanroom operations
  • Experience with facility and utility management, including HVAC, clean steam, and water systems in a GMP environment
Responsibilities
  • Lead the engineering activities, setting clear goals and priorities aligned with the company’s operational objectives and long-term growth plans. Develop and implement strategic initiatives for the engineering department, ensuring alignment with GMP and regulatory requirements.
  • Oversee new equipment and systems' design, installation, and qualification, including bioreactors, chromatography, filling lines, and HVAC systems. Ensure that all systems meet GMP standards and support manufacturing operations efficiently.
  • Ensure all engineering projects and systems meet GMP requirements and are validated according to regulatory guidelines (e.g., FDA, EMA). Oversee and perform equipment qualification (IQ/OQ/PQ) and facility validation activities, ensuring proper documentation and compliance.
  • Manage capital projects from concept through completion, including budgeting, timelines, resource allocation, and contractor management. Lead projects for equipment installations in support of client needs.
  • Develop and implement preventive and predictive maintenance programs to ensure equipment reliability and minimize downtime. Ensure timely maintenance of critical manufacturing equipment and utilities such as clean steam, purified water, and HVAC systems.
  • Identify opportunities to improve manufacturing processes through engineering solutions. Collaborate with the operations, quality, and automation teams to optimize throughput, reduce waste, and enhance process reliability.
  • Lead and mentor a team of engineers and technicians, fostering a culture of collaboration, innovation, and continuous learning. Provide technical guidance and support for troubleshooting equipment and process issues.
  • Work with facility management to ensure the operation, maintenance, and optimization of critical utilities, including purified water systems, clean steam generation, HVAC systems, and waste management, comply with regulatory and environmental standards.
  • Manage the engineering budget, including capital expenditures, operational expenses, and cost control measures. Identify and justify capital investment opportunities for equipment and facility upgrades.
  • Manage relationships with external vendors, contractors, and service providers to ensure timely project execution, procurement of high-quality equipment, and adherence to budget and timeline constraints
Desired Qualifications
  • Advanced degree or professional engineering certification (e.g., Professional Engineer)
  • Strong knowledge of engineering systems, processes, and utilities in a biotech manufacturing environment
  • Ability to quickly ramp up activity with minimal resources and guidance
  • Proven ability to troubleshoot and resolve complex engineering challenges in a manufacturing setting
  • Ability to lead and mentor a team of engineers, fostering growth and promoting a high-performance culture
  • Skilled at managing multiple projects, ensuring completion within budget and timeline while maintaining quality standards
  • Deep understanding of GMP requirements, regulatory compliance, and validation procedures in biotech/pharma settings
  • Identification with our core values: Sustainability, Openness, Enjoyment

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Goldman Sachs upgrades Sartorius Stedim Biotech to Buy rating.
  • Sartorius achieves 3.5 billion euros sales revenue in 2025.
  • Management forecasts 5-9% sales growth for 2026 with MATTEK contributions.

What critics are saying

  • Thermo Fisher undercuts Sartorius bioreactors, capturing 15-20% market share.
  • Danaher's Cytiva launches Sartocon competitor with 30% higher throughput.
  • Chinese clones replicate Arium Mini at 40% lower cost, eroding Asia sales.

What makes Sartorius unique

  • Sartorius launches Arium Mini Extend for versatile Type 1 water dispensing.
  • Sartorius opens $100M Bioanalytics CoE in Ann Arbor, Michigan.
  • Sartorius partners with Sanofi on downstream process intensification.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

IT Juzi
Aug 12th, 2025
Nanotein secures $3M strategic investment

Nanotein, a cell therapy developer, has secured a $3 million strategic investment from Sartorius Stedim Biotech.

INACTIVE